Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400354 | 0.85 | ABCB11 (0.34) | ALDH1A1MAPTSMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL6400707 | 0.81 | DYRK3 (0.31) | MAPTMPOMEN1KMT2A | |
| SCHEMBL6983641 | 0.80 | MEN1 (0.46) | ALDH1A1MAPTPKMSMN1; SMN2MEN1 | |
| SCHEMBL6398808 | 0.78 | PDE4D (0.39) | MASP2ALDH1A1MAPTPKMSMN1; SMN2 | |
| SCHEMBL6405742 | 0.72 | KRAS (0.39) | MASP2NPC1 | |
| SCHEMBL6400452 | 0.69 | EPHX1 (0.35) | MPO | |
| SCHEMBL6400583 | 0.69 | MASP2 (0.37) | MASP2ALDH1A1MAPT | |
| SCHEMBL10997002 | 0.68 | CYP2C9 (0.45) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6982024 | 0.68 | FAAH (0.44) | ALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL6403012 | 0.68 | FAAH (0.44) | ALDH1A1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1301509-A1 | MULTIFUNCTIONAL COUPLING AGENTS WITH CYCLIC IMINOESTER AND IMINOETHER GROUPS, METHOD FOR PRODUCING THE SAME AND USE THEREOF | Institut für Polymerforschung Dresden E.V. (DE) | 2003-04-16 | — | — | EP | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002004441-A1 | MULTIFUNCTIONAL COUPLING AGENTS WITH CYCLIC IMINOESTER AND IMINOETHER GROUPS, METHOD FOR PRODUCING THE SAME AND USE THEREOF | INSTITUT FÜR POLYMERFORSCHUNG DRESDEN E.V. (DE) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | MASP2 1503/4885ALDH1A1 945/4885MAPT 4864/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | MASP2 1454/4885ALDH1A1 356/4885MAPT 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.